Close Menu

NEW YORK (GenomeWeb) – Qiagen said Wednesday after the close of the market that that it has signed an agreement with McKesson Medical-Surgical, an affiliate of McKesson, to serve as the exclusive distributor of the QiaStat-Dx syndromic testing platform in the "acute" market segment of US hospitals with 200 or fewer beds.

The agreement also makes McKesson a non-exclusive distributor for QiaStat-Dx's future expansion into clinics located in US retail pharmacies.

Qiagen said it will continue its sales and marketing efforts in larger hospitals and clinical laboratories.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.